^
Association details:
Biomarker:HRAS G13R
Cancer:Solid Tumor
Drug:Mekinist (trametinib) (MEK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast

Published date:
09/08/2021
Excerpt:
All malignant AMEs presented a recurrent mutation in the HRAS G13R or G12S hotspot....Treatment of the PDX by the MEK inhibitor trametinib, resulted in a marked anti-tumor activity, in contrast to the BRAF inhibitor and the different chemotherapies that were ineffective. Overall, these findings further expand on the genetic features of AMEs and suggest that patients carrying advanced HRAS-mutated AMEs could potentially be treated with MEK inhibitors.
DOI:
10.1186/s13045-021-01158-3